Cargando…

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review

Pembrolizumab is widely used in first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression. The activity of pembrolizumab in NSCLC patients with rare molecular alterations is poorly characterised. RET gene rearrangements are identified in 1–2% of lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Knetki-Wróblewska, Magdalena, Wojas-Krawczyk, Kamila, Kowalski, Dariusz M., Krzakowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949444/
https://www.ncbi.nlm.nih.gov/pubmed/35329956
http://dx.doi.org/10.3390/jcm11061630
_version_ 1784674897710022656
author Knetki-Wróblewska, Magdalena
Wojas-Krawczyk, Kamila
Kowalski, Dariusz M.
Krzakowski, Maciej
author_facet Knetki-Wróblewska, Magdalena
Wojas-Krawczyk, Kamila
Kowalski, Dariusz M.
Krzakowski, Maciej
author_sort Knetki-Wróblewska, Magdalena
collection PubMed
description Pembrolizumab is widely used in first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression. The activity of pembrolizumab in NSCLC patients with rare molecular alterations is poorly characterised. RET gene rearrangements are identified in 1–2% of lung cancer patients. Here, we present two cases of RET-rearranged NSCLC patients with high PD-L1 expression (>50%), treated with pembrolizumab within routine clinical practice. Pembrolizumab was ineffective in both cases—single-agent immunotherapy seems to be of limited value in this group of patients. Selective RET-inhibitors, if available, are the optimal treatment for patients with RET fusion nowadays. The best sequence of the therapy is still not defined.
format Online
Article
Text
id pubmed-8949444
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89494442022-03-26 Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kowalski, Dariusz M. Krzakowski, Maciej J Clin Med Review Pembrolizumab is widely used in first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression. The activity of pembrolizumab in NSCLC patients with rare molecular alterations is poorly characterised. RET gene rearrangements are identified in 1–2% of lung cancer patients. Here, we present two cases of RET-rearranged NSCLC patients with high PD-L1 expression (>50%), treated with pembrolizumab within routine clinical practice. Pembrolizumab was ineffective in both cases—single-agent immunotherapy seems to be of limited value in this group of patients. Selective RET-inhibitors, if available, are the optimal treatment for patients with RET fusion nowadays. The best sequence of the therapy is still not defined. MDPI 2022-03-15 /pmc/articles/PMC8949444/ /pubmed/35329956 http://dx.doi.org/10.3390/jcm11061630 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Knetki-Wróblewska, Magdalena
Wojas-Krawczyk, Kamila
Kowalski, Dariusz M.
Krzakowski, Maciej
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
title Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
title_full Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
title_fullStr Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
title_full_unstemmed Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
title_short Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
title_sort non-small-cell lung cancer patients with coexistence of high pd-l1 expression and ret fusion—which path should we follow? case reports and literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949444/
https://www.ncbi.nlm.nih.gov/pubmed/35329956
http://dx.doi.org/10.3390/jcm11061630
work_keys_str_mv AT knetkiwroblewskamagdalena nonsmallcelllungcancerpatientswithcoexistenceofhighpdl1expressionandretfusionwhichpathshouldwefollowcasereportsandliteraturereview
AT wojaskrawczykkamila nonsmallcelllungcancerpatientswithcoexistenceofhighpdl1expressionandretfusionwhichpathshouldwefollowcasereportsandliteraturereview
AT kowalskidariuszm nonsmallcelllungcancerpatientswithcoexistenceofhighpdl1expressionandretfusionwhichpathshouldwefollowcasereportsandliteraturereview
AT krzakowskimaciej nonsmallcelllungcancerpatientswithcoexistenceofhighpdl1expressionandretfusionwhichpathshouldwefollowcasereportsandliteraturereview